Determine genetic variants and copy number changes associated with a poor, intermediate or ultra-rapid CYP2D6 metabolizer status.

Differences in the activity of the liver enzyme CYP2D6 contribute to the inter-individual variability in a majority of drug responses. The PGX-CYP2D6 XL StripAssay® in combination with the CYP2D6 RealFastTM CNV Assay detects the most common variations (genetic variants as well as copy number changes) in Caucasians, which are associated with a poor, intermediate or ultrarapid CYP2D6 metabolizer status.

 

PGX-CYP2D6

 

  • CYP2D6 is involved in the metabolism of about 25% of all drugs used in the clinic (e.g. tamoxifen, opiates, antidepressives or antipsychotics).
  • CYP2D6 loss-of-function alleles: *3 - *8, *11, *12, *15, *40, *58, *114
  • CYP2D6 reduced function alleles: *9, *10, *14, *17, *29, *41
  • CYP2D6 increased function alleles: *1xN, *2xN, *35xN (N= copy number)
  • Clinical guidelines on drug prescription recommendations are listed on PharmGKB: www.pharmgkb.org
  • Around 6 % of Europeans are poor, 7% are intermediate and 3 % are ultrarapid metabolizers.
  • The PGX-CYP2D6 XL StripAssay® in combination with the CYP2D6 RealFastTM CNV Assay can identify patients with altered CYP2D6 enzyme function. This facilitates the choice of medication and/or the adjustment of drug dosage, thereby reducing the risk of adverse events or lowered treatment efficacy.

 

ProductREFUnit SizeIFUBrochure
PGX-CYP2D6 StripAssay®4-76020 tests

PDF

PDF